5 more manufactures given license to produce drug used to treat black fungus: Govt
Efforts are being made to supplement the domestic availability of the anti-fungal drug through import, the ministry said, adding that 3,63,000 vials of Amphotericin-B will be imported in May, resulting in the total availability of 5,26,752 vials (inclusive of the domestic production) in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2021 Category: Pharmaceuticals Source Type: news
Black fungus: 11 firms to produce Amphotericin-B drug to fight disease
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 20, 2021 Category: Pharmaceuticals Source Type: news
Amphotericin-B: Concern over 'black fungus' drug shortage as cases rise
The intravenous injection is in short supply as hospitals report a spike in cases. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 19, 2021 Category: Consumer Health News Source Type: news
Delhi govt sets up panel for timely distribution of Amphotericin-B injection to hospitals
Hospitals in Delhi have reported a rise in the number of back fungus cases among people recovering from COVID-19 during the second wave and it could be ascribed to "irrational" use of steroids at home without consulting a doctor. (Source: The Economic Times)
Source: The Economic Times - May 19, 2021 Category: Consumer Health News Source Type: news
Genetek Lifesciences to manufacture Amphotericin B injection for black fungus treatment
Genetek Lifesciences started production of Remdesivir injections, used in the treatment of COVID-19, in Wardha from Wednesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 14, 2021 Category: Pharmaceuticals Source Type: news
Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study, Clinical Infectious Diseases
Conclusions Aspergillus ustus IA mainly occurred in nonneutropenic transplant patients and was frequently associated with extrapulmonary sites of infection. Mortality rate was high and optimal antifungal therapy remains to be defined. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 13, 2021 Category: Consumer Health News Source Type: news
Cochrane review informs guidelines on managing histoplasmosis in people living with HIV
In a newsystematic review, an author team from the Cochrane Infectious Diseases Group explored the evidence regarding managing histoplasmosis in people with HIV. Their review informed the PAHO/WHO guideline development process. The review authors worked with the guideline development group to formulate key questions, including which antifungal drug to start, how long to continue, and when to start antiretroviral medication. They also looked at tuberculosis therapy when people were infected with tuberculosis, HIV, and histoplasmosis.Histoplasmosis is an infection caused by inhaling a fungus called Histoplasma. The mos...
Source: Cochrane News and Events - August 11, 2020 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Spectrophotometric MICs reading of azoles and amphotericin B shows high agreement with visual reading MIC interpretation using EUCAST 9.3.1 methodology
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 24, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news
Evaluating prophylactic post cardiac transplantation amphotericin B treatment by simulation
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 24, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news
Development of novel oral formulation to treat systemic fungal infections
(Bentham Science Publishers) The Wasan Laboratory in the Faculty of Pharmaceutical Sciences at the University of British Columbia in partnership with iCo Therapeutics Inc. (Vancouver BC, Canada) have developed a novel oral formulation of Amphotericin B to treat systemic fungal and parasitic infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 23, 2020 Category: Infectious Diseases Source Type: news
Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole Resistant Aspergillus fumigatus Strains
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 30, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Two cases of Pseudomembranous Tracheobronchitis due to Amphotericin B-resistant Aspergillus flavus
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 10, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Evaluation of 99mTc-Amphotericin B for nuclear imaging of mould infections in a transwell in vitro system
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 9, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Antifungal prophylaxis with nebulized liposomal amphotericin B and fluconazole is effective and safe in the early phase of allogenic hematopoietic stem cell transplantation
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 19, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Antifungal prophylaxis with micafungin and bridging to inhaled liposomal amphotericin B after engraftment in patients undergoing allogeneic hematopoietic stem cell transplantation
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 19, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
